OHSU/Knight Cancer Institute is an innovator in early breast cancer treatment by offering Intrabeam Radiotherapy for eligible patients’ lumpectomies. This radiotherapy offers one targeted radiation dose, intraoperatively, as compared to six weeks of conventional external radiation treatment.

CASE STATEMENT:
OHSU/Knight Cancer Institute is the only medical center in the Pacific Northwest to employ the Intrabeam Radiotherapy System for the targeted delivery of early breast cancer treatment.

IMPACTS ON HEALTH CARE COSTS:
- Reducing radiation treatments from six weeks to one day potentially results in an **83 percent cost savings** compared to traditional breast cancer treatment.
- The accuracy of this radiation therapy allows the patient to recover more quickly, spending less time in a health care facility and returning to life sooner.

BENEFITS TO YOUR EMPLOYEES:
- Intrabeam radiotherapy, delivered at the time of surgery, allows eligible patients to dramatically reduce the need for conventional radiation treatment, one day vs. six weeks, resulting in a quicker patient recovery and return to work.
- The Intrabeam intraoperative radiotherapy delivers a precise dose directly to the affected tissue, ensuring the effectiveness of the treatment.
- The convenient single-dose radiation treatment reduces the number of physician visits for the patient, resulting in more time on the job.
- The targeted therapy results in: less irritation to healthy breast tissue, minimizes exposure to other organs and fewer negative skin reactions.
- No treatment delay for those patients who must undergo chemotherapy as part of their breast cancer treatment.

BOTTOM LINE:
Providing cutting-edge, precise breast cancer therapy results in less downtime for the patient and reduced cost and time spent receiving traditional radiation treatment. Just one more reason why it’s good business to ensure OHSU is included in your benefits plan.

When it comes to serious medicine, OHSU is irreplaceable in your benefits plan.